Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus
The clinical spectrum of systemic lupus erythematosus (SLE) is highly heterogeneous, ranging from mild disease, which can be limited to skin and joint involvement, to life-threatening conditions with renal impairment, severe cytopenias, central nervous system disease, and thromboembolic events. Apar...
Saved in:
Other Authors: | , |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_96622 | ||
005 | 20230202 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20230202s2023 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-6109-7 | ||
020 | |a 9783036561103 | ||
020 | |a 9783036561097 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-6109-7 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
100 | 1 | |a Sjöwall, Christopher |4 edt | |
700 | 1 | |a Parodis, Ioannis |4 edt | |
700 | 1 | |a Sjöwall, Christopher |4 oth | |
700 | 1 | |a Parodis, Ioannis |4 oth | |
245 | 1 | 0 | |a Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
300 | |a 1 electronic resource (208 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a The clinical spectrum of systemic lupus erythematosus (SLE) is highly heterogeneous, ranging from mild disease, which can be limited to skin and joint involvement, to life-threatening conditions with renal impairment, severe cytopenias, central nervous system disease, and thromboembolic events. Apart from the host genetics, several environmental factors, such as sunlight, infections, drugs, and probably hormonal factors, can trigger the onset of symptoms related to SLE. Despite significant advances in our understanding of the pathophysiology and optimization of medical care, patients with SLE still have significant rates of premature mortality and many patients experience severe disease with increased risk of sustaining organ damage and having a reduced health-related quality of life. The development of effective drugs that can induce remission or low disease activity, the unanimous use of definitions of remission and low or high disease activity, flare, and response to therapy, the identification of non-invasive biomarkers of disease activity and long-term outcomes, and the implementation of SLE patients' perspectives as an integral part of the clinical assessment constitute only a few of the many unmet needs in the field of SLE. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
653 | |a systemic lupus erythematosus | ||
653 | |a quality of life | ||
653 | |a cross-sectional studies | ||
653 | |a surveys and questionnaires | ||
653 | |a rheumatoid arthritis | ||
653 | |a fatigue | ||
653 | |a pain | ||
653 | |a psychosocial | ||
653 | |a disease activity | ||
653 | |a health-related quality of life | ||
653 | |a patient-reported outcomes | ||
653 | |a clinical follow-up | ||
653 | |a outcome measures | ||
653 | |a abnormal liver function tests | ||
653 | |a autoimmune liver diseases | ||
653 | |a autoimmune hepatitis | ||
653 | |a hepatic involvement | ||
653 | |a liver biopsy | ||
653 | |a primary biliary cholangitis | ||
653 | |a COVID-19 | ||
653 | |a hydroxychloroquine | ||
653 | |a glucocorticoids | ||
653 | |a epidemiology | ||
653 | |a Systemic Lupus Erythematosus | ||
653 | |a outcome | ||
653 | |a mortality | ||
653 | |a survival | ||
653 | |a end-stage renal disease | ||
653 | |a cancer | ||
653 | |a cardiovascular disease | ||
653 | |a infections | ||
653 | |a neoplasm | ||
653 | |a hospital admissions | ||
653 | |a medication adherence | ||
653 | |a compliance | ||
653 | |a patient perspective | ||
653 | |a qualitative research | ||
653 | |a classification | ||
653 | |a cluster analysis | ||
653 | |a laboratory | ||
653 | |a linear discriminant analysis | ||
653 | |a genetics | ||
653 | |a chronic damage | ||
653 | |a polymorphisms | ||
653 | |a TNFSF4 | ||
653 | |a MIR1279 | ||
653 | |a Ki/SL | ||
653 | |a proteasome | ||
653 | |a autoantibodies | ||
653 | |a lupus | ||
653 | |a SLE | ||
653 | |a Sjögren syndrome | ||
653 | |a flare | ||
653 | |a damage | ||
653 | |a long disease duration | ||
653 | |a trajectories | ||
653 | |a remission | ||
653 | |a low disease activity | ||
653 | |a comorbidities | ||
653 | |a mood disorders | ||
653 | |a low-disease activity | ||
653 | |a patient outcome | ||
653 | |a Afro-Caribbean | ||
653 | |a systemic lupus | ||
653 | |a lupus nephritis | ||
653 | |a long-term prognosis | ||
653 | |a dehydroepiandrosterone | ||
653 | |a SLEDAI-2K | ||
653 | |a n/a | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/6567 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/96622 |7 0 |z DOAB: description of the publication |